Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fate Therapeutics (FATE) Non-Current Deffered Revenue (2016 - 2022)

Historic Non-Current Deffered Revenue for Fate Therapeutics (FATE) over the last 11 years, with Q3 2022 value amounting to $12.4 million.

  • Fate Therapeutics' Non-Current Deffered Revenue fell 6189.85% to $12.4 million in Q3 2022 from the same period last year, while for Sep 2022 it was $12.4 million, marking a year-over-year decrease of 6189.85%. This contributed to the annual value of $27.1 million for FY2021, which is 4106.17% down from last year.
  • According to the latest figures from Q3 2022, Fate Therapeutics' Non-Current Deffered Revenue is $12.4 million, which was down 6189.85% from $17.7 million recorded in Q2 2022.
  • In the past 5 years, Fate Therapeutics' Non-Current Deffered Revenue ranged from a high of $54.7 million in Q2 2020 and a low of $1.3 million during Q1 2018
  • For the 5-year period, Fate Therapeutics' Non-Current Deffered Revenue averaged around $20.3 million, with its median value being $12.4 million (2022).
  • Per our database at Business Quant, Fate Therapeutics' Non-Current Deffered Revenue surged by 127724.07% in 2021 and then tumbled by 6189.85% in 2022.
  • Fate Therapeutics' Non-Current Deffered Revenue (Quarter) stood at $7.5 million in 2018, then plummeted by 49.67% to $3.8 million in 2019, then soared by 1119.1% to $46.0 million in 2020, then tumbled by 41.06% to $27.1 million in 2021, then crashed by 54.26% to $12.4 million in 2022.
  • Its Non-Current Deffered Revenue stands at $12.4 million for Q3 2022, versus $17.7 million for Q2 2022 and $22.5 million for Q1 2022.